Remimazolam Intervention
Phase 1Small molecule
Remimazolam Intervention is one of 47 small molecule programs targeting Delirium. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
78 competitors in Delirium
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Exelon
NovartisApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Aleve
Jazz PharmaceuticalsApproved
Voltaren
NovartisApproved
Duragesic
CCephalon
Approved
Anerem
AAcacia Pharma Ltd
Approved
Spravato
WWim Janssens
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Tylenol
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Delirium1 trial
Effect of Remimazolam Versus Dexmedetomidine on the Incidence of Delirium After Elective Cardiac Surgery with Cardiopulmonary Bypass: a Prospective Randomized Controlled Trial
Not yet recruiting·—·Phase 1·NCT06756178·111 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Remimazolam Intervention. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAssiut University